Blood purification therapy for sepsis

被引：10
作者：
Sakata, Hiromi [1 ]
Yonekawa, Motoki [1 ]
Kawamura, Akio [1 ]
机构：
[1] Sapporo Hokuyu Hosp, Dept Surg, Res Inst Artificial Organs Transplantat & Gene Th, Shiroishi Ku, Sapporo, Hokkaido 0030006, Japan
来源：
TRANSFUSION AND APHERESIS SCIENCE | 2006年 / 35卷 / 03期
关键词：
D O I：
10.1016/j.transci.2006.06.003
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Accumulating evidences Of underlining pathogenesis of sepsis have contributed to the therapeutic strategy for sepsis. Not only endotoxin and cytokine, but also signal transduction through Toll-like receptors could be a strategic target for the management of sepsis. Blood purification therapy including polymyxin B-immobilized hemoperfusion cartridge and continuous hemodialiltration has shown the beneficial effect on patients with sepsis in Japan. Although they were initially designed to remove endotoxin and cytokines respectively, they might eliminate unexpected mediators responsible for sepsis. Further elucidation of mechanism and randomized controlled studies are needed to establish the role of blood purification therapy in sepsis. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码：245 / 251
页数：7
相关论文
共 41 条
[1]   EFFICACY AND SAFETY OF MONOCLONAL-ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR-ALPHA IN PATIENTS WITH SEPSIS SYNDROME - A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL-TRIAL [J].
ABRAHAM, E ;
WUNDERINK, R ;
SILVERMAN, H ;
PERL, TM ;
NASRAWAY, S ;
LEVY, H ;
BONE, R ;
WENZEL, RP ;
BALK, R ;
ALLRED, R ;
PENNINGTON, JE ;
WHERRY, JC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (12) :934-941
[2]   Toll-like receptor signalling [J].
Akira, S ;
Takeda, K .
NATURE REVIEWS IMMUNOLOGY, 2004, 4 (07) :499-511
[3]   CONTINUOUS VENOVENOUS HEMOFILTRATION WITH DIALYSIS REMOVES CYTOKINES FROM THE CIRCULATION OF SEPTIC PATIENTS [J].
BELLOMO, R ;
TIPPING, P ;
BOYCE, N .
CRITICAL CARE MEDICINE, 1993, 21 (04) :522-526
[4]   THE ACCP-SCCM CONSENSUS CONFERENCE ON SEPSIS AND ORGAN FAILURE [J].
BONE, RC ;
SIBBALD, WJ ;
SPRUNG, CL .
CHEST, 1992, 101 (06) :1481-1482
[5]   Sepsis: A new hypothesis for pathogenesis of the disease process [J].
Bone, RC ;
Grodzin, CJ ;
Balk, RA .
CHEST, 1997, 112 (01) :235-243
[6]  
Canaud B, 1995, Adv Nephrol Necker Hosp, V24, P271
[7]   The immunopathogenesis of sepsis [J].
Cohen, J .
NATURE, 2002, 420 (6917) :885-891
[8]   A phase II randomized, controlled trial of continuous hemofiltration in sepsis [J].
Cole, L ;
Bellomo, R ;
Hart, G ;
Journois, D ;
Davenport, P ;
Tipping, P ;
Ronco, C .
CRITICAL CARE MEDICINE, 2002, 30 (01) :100-106
[9]   Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein [J].
Fisher, CJ ;
Agosti, JM ;
Opal, SM ;
Lowry, SF ;
Balk, RA ;
Sadoff, JC ;
Abraham, E ;
Schein, RMH ;
Benjamin, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (26) :1697-1702
[10]   INITIAL EVALUATION OF HUMAN RECOMBINANT INTERLEUKIN-1 RECEPTOR ANTAGONIST IN THE TREATMENT OF SEPSIS SYNDROME - A RANDOMIZED, OPEN-LABEL, PLACEBO-CONTROLLED MULTICENTER TRIAL [J].
FISHER, CJ ;
SLOTMAN, GJ ;
OPAL, SM ;
PRIBBLE, JP ;
BONE, RC ;
EMMANUEL, G ;
NG, D ;
BLOEDOW, DC ;
CATALANO, MA ;
FRIEDMAN, B ;
MURE, A ;
SHAPIRO, E .
CRITICAL CARE MEDICINE, 1994, 22 (01) :12-21
12345